Chronic Hepatitis C Treatment in a Thalassemia Major Patient: A Case Report

Thalassemia major patients with chronic hepatitis C have increased risk for developing fibrosis and hepatocellular carcinoma due to liver damage caused by these two diseases. Although the current treatment of chronic hepatitis is based on binary combinations, the use of ribavirin in combination with peginterferon alfa-2a or b in patients with hemoglobinopathies is not recommended by the treatment guidelines. However, it is observed that there have been changes in the applications presented in the guidelines over the years. This paper presents the outcomes and side effects of treatment given to thalassemia major patients with chronic hepatitis C.